New hope for bone marrow failure patients as experimental drug trial begins
NCT ID NCT07297550
Summary
This study is testing whether adding a new drug called a JAK1 inhibitor to standard immune-suppressing therapy can help people with severe aplastic anemia. The trial has two parts: first testing safety in patients whose disease hasn't responded to standard treatment, then testing effectiveness in newly diagnosed patients. The main goals are to see if the combination is safe and if it can restore normal blood cell counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.